SCHEMBL9637331

SCHEMBL9637331

CCCCCCCCOc1ccc(-c2ccc(-c3ncc(CCCCCCCC)cn3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RARB P10826 4/20 0.62
RAB9A P51151 5/20 0.61
KDM4E B2RXH2 4/20 0.61
NPC1 O15118 3/20 0.61
SMN1; SMN2 Q16637 3/20 0.61
HSD17B10 Q99714 2/20 0.61
ALDH1A1 P00352 4/20 0.58
MAPT P10636 3/20 0.58
HPGD P15428 3/20 0.58
MEN1 O00255 2/20 0.58
USP2 O75604 2/20 0.58
KMT2A Q03164 2/20 0.58
GAA P10253 1/20 0.58
L3MBTL1 Q9Y468 2/20 0.55
CYP3A4 P08684 3/20 0.51
CYP2D6 P10635 2/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9636114 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9435062 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9637628 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9637749 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9637319 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9434594 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9636331 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9435215 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9637343 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2
SCHEMBL9637541 1.00 RARB (0.62) RARBRAB9AKDM4ENPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883037-B2 Chiral compounds, cholesteric and ferroelectric liquid crystal compositions comprising these chiral compounds, and liquid crystal displays comprising these liquid crystal compositions TETRAGON LC CHEMIE AG (LI) 2014-11-11 US disclosed
US-20140327862-A1 FERROELECTRIC LIQUID CRYSTAL COMPOSITION AND FERROELECTRIC LIQUID CRYSTAL DISPLAY DEVICE DIC CORPORATION (JP) 2014-11-06 US disclosed
US-20130228720-A1 CHIRAL COMPOUNDS, CHOLESTERIC AND FERROELECTRIC LIQUID CRYSTAL COMPOSITIONS COMPRISING THESE CHIRAL COMPOUNDS, AND LIQUID CRYSTAL DISPLAYS COMPRISING THESE LIQUID CRYSTAL COMPOSITIONS TETRAGON LC CHEMIE AG (LI) 2013-09-05 US disclosed
US-20110233463-A1 CHIRAL COMPOUNDS, CHOLESTERIC AND FERROELECTRIC LIQUID CRYSTAL COMPOSITIONS COMPRISING THESE CHIRAL COMPOUNDS, AND LIQUID CRYSTAL DISPLAYS COMPRISING THESE LIQUID CRYSTAL COMPOSITIONS TETRAGON LC CHEMIE AG 2011-09-29 US disclosed
EP-0293763-B1 SMECTIC LIQUID CRYSTAL MIXTURE CHISSO CORPORATION (JP) 1992-07-29 EP disclosed
US-4882083-A CONTAINING OPTICALLY ACTIVE COMPOUND; HIGH SPEED RESPONSE DISPLAY ELEMENT CHISSO CORPORATION (JP) 1989-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110233463-A1 CHIRAL COMPOUNDS, CHOLESTERIC AND FERROELECTRIC LIQUID CRYSTAL COMPOSITIONS COMPRISING THESE CHIRAL COMPOUNDS, AND LIQUID CRYSTAL DISPLAYS COMPRISING THESE LIQUID CRYSTAL COMPOSITIONS NR1H2, NR1H3, NR1H4 RARB 628/4885RAB9A 2741/4885KDM4E 1112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.